nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
您当前所在位置: 首页> 文献列表> 热哮汤治疗支气管哮喘急性发作期临床研究
2019, 21, v.25 1628-1631
热哮汤治疗支气管哮喘急性发作期临床研究
基金项目(Foundation): 贵州省科技合作计划项目(黔科合LH字[2016]7134号); 2016年贵阳市科技计划项目(筑科合同(20161001)号)~~
邮箱(Email):
DOI: 10.13210/j.cnki.jhmu.20190929.001
发布时间: 2019-09-29
出版时间: 2019-09-29
网络发布时间: 2019-09-29
移动端阅读
摘要:

目的:对名中医王玉林自拟方热哮汤对急性期支气管哮喘(BA)的安全性和疗效、机制进行临床研究。方法:将80例急性发作期BA患者随机分成西医组40例、中西医组40例。西医组以西医常规治疗:沙美特罗替卡松每次1吸,吸入每日2次,配合氧疗及诱因治疗。中西医组在西医组治疗基础上联合热哮汤煎服,疗程15 d。观察证候评分、血气分析(PaCO2、 PaO2),诱导痰IL-5、EOS、IL-13、肺功能(PEF%Pred、FEV1%Pred),中西医组的肾、肝功能、血常规,记录不良反应。结果:两组总有效率比较,差异具有统计学意义(P<0.01)。中西医组在治疗后对中医证候积分改善优于西医组(P<0.05)。中西医组于治疗后肺功能(FEV1%Pred)改善优于西医组(P<0.01),中西医组PEF%Pred较西医组改善(P<0.05)。中西医组治疗后血气分析(PaO2)上升较西医组明显(P<0.05),两组治疗后对血气分析(PaCO2)改进无显著差异(P>0.05)。中西医组治疗后痰IL-13、EOS及IL-5降低较西医组多(P<0.01)。中西医组治疗前后肝功能(AST、ALT)、肾功能(Cr、Urea)、血常规(WBC、 RBC、 PLT)比较,差异均无统计学意义(P>0.05);未见明显不良反应。结论:热哮汤治疗急性发作期支气管哮喘热哮证安全且有效,作用靶点与降低炎症因子和嗜酸性粒细胞相关可能性大,致气道炎症影响及高反应降低。

Abstract:

Objective: To study the safety, efficacy and mechanism of Wang Yulin self-made recipe Rexiao decoction in the treatment of acute bronchial asthma. Methods:A total of 80 patients with acute bronchial asthma were randomly divided into the western medicine group(control group, n=40) and the traditional Chinese and western medicine group(n=40). The control group was treated with routine western medicine: salmeterol was inhaled twice a day, combined with oxygen therapy and inducement therapy; while the Chinese and western medical group was treated with Rexiao decoction based onthe western medical group. The course of treatment in the Chinese and western medical groupwas15 days. The syndrome score, blood gas analysis(PaCO2, PaO2) and induced sputum IL-5, EOS, IL-1,and pulmonary function(PEF% Pred, FEV1% Pred)were observed;kidney, liver function, blood routine, and adverse reactions wererecorded. Results:The total effective rate was 85% in the western medicine group and 92.5%in the traditional Chinese and western medicine group(P<0.01). After treatment, the score of TCM syndromes in the Chinese and western medicine group was better than that in the western medicine group(P<0.05). After treatment, the pulmonary function(FEV1% Pred) of the traditional Chinese and western medicine group was better than that of the western medicine group, and the PEF% Pred of the Chinese and western medicine group was better than that of the western medicine group. The blood gas(PaO2)in the traditional Chinese and western medicine group after treatment was significantly higher than that in the control group(P<0.05). There was no significant difference in the improvement of blood gas analysis(PaCO2) between the western medicine group and the traditional Chinese and western medicine group(P>0.05). The decrease of IL-13,EOS and IL-5 in sputum of the traditional Chinese and western medicine group was more than that of the western medicine group(P<0.01). There was no significant difference in liver function(AST, ALT), renal function(Cr, Urea), blood routine(WBC, RBC, PLT) before and after treatment in traditional Chinese and western medicine group(P>0.05), but no obvious adverse reactions were found. Conclusion:Rexiao decoction is safe and effective in the treatment of asthma of heat wheezing type at the acute stage. The target and inflammatory factors, eosinophils are likely to decrease, and the effect of airway inflammation and high reaction are decreased.

参考文献

1 GBD Causes of Death Collaborators.Global,regional,and national age-sex specific mortality for 264 causes of death,1980-2016:a systematic analysis for the Global Burden of Disease Study 2016[J].Lancet,2017,390(10100):1151-1210.

2 冯晓凯.中华医学会呼吸病学分会哮喘学组,支气管哮喘防治指南[J].柳州医学,2012,03:171-179.

3 侯亚青,宋平.从气机升降论治咳嗽[J].现代中医药,2017,37(1):59,62.

4 马以泉,王仁忠,曹灵勇.麻杏石甘汤药理作用研究[J].中国药业,2005,14(4):32-33.

5 杨昆,徐升,王飞,等.从“风痰”论治支气管哮喘的病因病机研究[J].中药与临床,2016,7(5):45-46.

6 蒋韵,吴芬芬.黄芩甙抗过敏机制的药理研究[J].中国实验临床免疫学杂志,1995,(3):7-9.

7 刘雨东,王美霞,邓跃林,等.栀子苷减轻幼年哮喘小鼠气道炎性反应并下调TLR4/NF-κB活性[J].基础医学与临床,2016,36(10):1417-1421.

8 樊兰兰,陆丽妃,王孝勋,等.百部药理作用与临床应用研究进展[J].中国民族民间医药,2017,26(8):55-59.

9 朱琴芳.乌梢蛇配伍临床应用举隅[J].云南中医学院学报,1996,19(1):31-32.

10 周明眉,褚襄萍,杨红舟,等.地龙酸性部位对小鼠过敏性哮喘模型的抗炎和抗过敏作用[J].中国中药杂志,2008,33(19):2249-2252.

11 黄庆,李志武,马志国,等.地龙的研究进展[J].中国实验方剂学杂志,2018,24(13):220-226.

12 张秋凤,李薇,吴晓东.气道重构的发病机制与地龙的药理作用[J].医学综述,2018,24(6):1115-1120.

13 苗雨露,张雯霞,王玉娥,等.清热解毒类中药抗炎机制研究进展[J].中国实验方剂学杂志,2018,24(9):228-234.

14 岳子强,陈琼科,吴清.金银花及蒲公英体外抑菌作用观察[J].实用中医药杂志,2018,34(2):264-265.

15 丁惠,张馨方,纪文华,等.蒲公英药用研究进展[J].辽宁中医药大学学报,2018,20(9):156-159.

16 青杰超,林子然,莫开林.金银花和蒲公英抑菌、抗氧化以及抗紫外作用初探[J].四川林业科技,2018,39(6):55-57.

17 黄楦槟,陈金水.苏子油的药理作用研究进展[J].光明中医,2015,30(9):2039-2041.

18 彭婉,马骁,王建,等.麦冬化学成分及药理作用研究进展[J].中草药,2018,49(2):477-488.

19 孙晓媛,于凡,肖伟,等.麦冬现代应用的研究进展[J].中国现代中药,2018,20(11):1453-1458.

20 曾凡玉,李思瑶,石锴.麦冬多糖的药理研究进展[J].海峡药学,2018,30(1):55-57.

基本信息:

DOI:10.13210/j.cnki.jhmu.20190929.001

中图分类号:R256.12

引用信息:

[1]周玉华,涂兴蕊,王叶,等.热哮汤治疗支气管哮喘急性发作期临床研究[J].海南医学院学报,2019,25(21):1628-1631.DOI:10.13210/j.cnki.jhmu.20190929.001.

基金信息:

贵州省科技合作计划项目(黔科合LH字[2016]7134号); 2016年贵阳市科技计划项目(筑科合同(20161001)号)~~

发布时间:

2019-09-29

出版时间:

2019-09-29

网络发布时间:

2019-09-29

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文